FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, namely to a method for producing a cell preparation based on activated lymphocytes from leukocyte filters. Method comprises recovery of lymphocytes on ficoll gradient, activation in culture flasks or plates in nutrient medium, resuspension of activated cytotoxic lymphocytes in supernatant and intracutaneous paravertebral introduction from 3rd day of activation, updating half the volume of the nutrient medium every 48 hours and distributing the supernatants into ampoules with volume of 1.3-2 ml, storage in a freezer for subsequent use in outpatient treatment.
EFFECT: method enables to obtain large doses – more than 300 million cells at a time – from one filter after activation of activated HLA-DR+ lymphocytes: T-cytotoxic cells CD3+CD8+ and NKT- cells CD3+CD16+CD56+ with high viability >96%, as well as to obtain supernatants containing high doses of cytokines produced by lymphocytes during activation in vitro: IL-2 >250 IU/ml, IL-6 >30 IU/ml, IL-10 >180 IU/ml, IFN-γ >550 IU/ml, TNF-α >100 IU/ml.
2 cl, 6 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PRODUCING CYTOTOXIC LYMPHOCYTES USING IFN-γ AND TNF-α FOR ADOPTIVE IMMUNOTHERAPY | 2023 |
|
RU2822876C2 |
METHOD FOR EXPANSION OF HUMAN NK CELLS USING FEEDER CELLS | 2021 |
|
RU2781777C2 |
METHOD OF CYTOGENETIC ACTIVATION OF HUMAN LYMPHOCYTES | 2015 |
|
RU2603079C2 |
METHOD FOR LONG-TERM CULTIVATION AND EXPANSION OF NK CELLS WITH HIGH VIABILITY AND FUNCTIONAL ACTIVITY | 2021 |
|
RU2794770C1 |
METHOD FOR PRODUCING ACTIVATED LEUKOCYTES FOR ADJUVANT ADOPTIVE IMMUNOTHERAPY OF MALIGNANT GROWTHS | 2009 |
|
RU2414915C2 |
METHOD OF TREATING ONCOLOGICAL PATIENTS WITH CYTOTOXIC LYMPHOCYTES | 2015 |
|
RU2596505C1 |
METHOD FOR PREPARING ACTIVATED MONONUCLEAR LEUKOCYTES | 2009 |
|
RU2402338C1 |
METHOD OF OBTAINING DEPOSITED LYMPHOKINE-ACTIVATED KILLER CELLS | 2009 |
|
RU2400238C1 |
METHOD OF TREATMENT OF PATIENTS WITH HERPES VIRUS INFECTION USING IN VITRO ACTIVATED AUTOLOGICAL LYMPHOCYTES | 2022 |
|
RU2799141C2 |
RECOMBINANT CELL LINE TMDK562-15 SHOWING THE ABILITY TO ACTIVATE AND PROLIFERATE HUMAN NK CELLS | 2022 |
|
RU2803178C1 |
Authors
Dates
2025-03-03—Published
2024-07-10—Filed